These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2528436)

  • 41. Hair Mineral and Trace Element Content in Children with Down's Syndrome.
    Grabeklis AR; Skalny AV; Skalnaya AA; Zhegalova IV; Notova SV; Mazaletskaya AL; Skalnaya MG; Tinkov AA
    Biol Trace Elem Res; 2019 Mar; 188(1):230-238. PubMed ID: 30209729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atlanto-occipital hypermobility in subjects with Down's syndrome.
    Matsuda Y; Sano N; Watanabe S; Oki S; Shibata T
    Spine (Phila Pa 1976); 1995 Nov; 20(21):2283-6. PubMed ID: 8553114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroanatomy of Down's syndrome: a high-resolution MRI study.
    Pinter JD; Eliez S; Schmitt JE; Capone GT; Reiss AL
    Am J Psychiatry; 2001 Oct; 158(10):1659-65. PubMed ID: 11578999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of a caffeine test for determining the phenotype of N-acetyltransferase].
    Gascon MP; Leemann T; Dayer P
    Schweiz Med Wochenschr; 1987 Dec; 117(49):1974-6. PubMed ID: 3423781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Down's syndrome in diabetic patients aged <20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes.
    Rohrer TR; Hennes P; Thon A; Dost A; Grabert M; Rami B; Wiegand S; Holl RW;
    Diabetologia; 2010 Jun; 53(6):1070-5. PubMed ID: 20186386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
    Grant DM; Mörike K; Eichelbaum M; Meyer UA
    J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urine excretion of caffeine and select caffeine metabolites is common in the U.S. population and associated with caffeine intake.
    Rybak ME; Sternberg MR; Pao CI; Ahluwalia N; Pfeiffer CM
    J Nutr; 2015 Apr; 145(4):766-74. PubMed ID: 25833779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maturation of AFMU excretion in infants.
    Pons G; Rey E; Carrier O; Richard MO; Moran C; Badoual J; Olive G
    Fundam Clin Pharmacol; 1989; 3(6):589-95. PubMed ID: 2613160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperthyrotropinaemia in untreated subjects with Down's syndrome aged 6 months to 64 years: a comparative analysis.
    Meyerovitch J; Antebi F; Greenberg-Dotan S; Bar-Tal O; Hochberg Z
    Arch Dis Child; 2012 Jul; 97(7):595-8. PubMed ID: 22535238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome.
    Teipel SJ; Schapiro MB; Alexander GE; Krasuski JS; Horwitz B; Hoehne C; Möller HJ; Rapoport SI; Hampel H
    Am J Psychiatry; 2003 Oct; 160(10):1870-8. PubMed ID: 14514503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maternal speech to normal and Down's syndrome children matched for mean length of utterance.
    Rondal JA
    Monogr Am Assoc Ment Defic; 1978; (3):193-265. PubMed ID: 155777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Morphometry of the ear in Down's syndrome subjects. A three-dimensional computerized assessment.
    Sforza C; Dellavia C; Tartaglia GM; Ferrario VF
    Int J Oral Maxillofac Surg; 2005 Jul; 34(5):480-6. PubMed ID: 16053865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Islet autoimmunity in children with Down's syndrome.
    Gillespie KM; Dix RJ; Williams AJ; Newton R; Robinson ZF; Bingley PJ; Gale EA; Shield JP
    Diabetes; 2006 Nov; 55(11):3185-8. PubMed ID: 17065360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers.
    Murayama N; Shimizu M; Kobayashi K; Kishimoto I; Yamazaki H
    Drug Metab Lett; 2017; 10(4):240-243. PubMed ID: 27842485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The aging of Down's Syndrome subjects].
    Fromage B; Anglade P
    Encephale; 2002; 28(3 Pt 1):212-6. PubMed ID: 12091781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acetylator phenotype in patients with p-phenylenediamine allergy.
    Kawakubo Y; Nakamori M; Schöpf E; Ohkido M
    Dermatology; 1997; 195(1):43-5. PubMed ID: 9267736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Noninvasive determination of acetaminophen disposition in Down's syndrome.
    Griener JC; Msall ME; Cooke RE; Corcoran GB
    Clin Pharmacol Ther; 1990 Nov; 48(5):520-8. PubMed ID: 2146059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maturation of caffeine metabolic pathways in infancy.
    Carrier O; Pons G; Rey E; Richard MO; Moran C; Badoual J; Olive G
    Clin Pharmacol Ther; 1988 Aug; 44(2):145-51. PubMed ID: 3396261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia.
    Aylward EH; Li Q; Honeycutt NA; Warren AC; Pulsifer MB; Barta PE; Chan MD; Smith PD; Jerram M; Pearlson GD
    Am J Psychiatry; 1999 Apr; 156(4):564-8. PubMed ID: 10200735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.